Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Here we profile companies developing innovations for women’s health, a relatively underfunded market with few treatment options available for many conditions.
For centuries, women’s health has been neglected across science, medicine and technology. A new report from the World Economic Forum suggests tackling this could unlock a $1 trillion economic boost with the potential to change the lives of 3.9 billion women.
Sano Chemicals, located in Bryan, Texas, specializes in the development of first-in-class drugs, with its current lead being the unique fungicide occidiofungin.
Coagulant Therapeutics is developing a novel pipeline of therapeutics to treat acute bleeds led by CT-001, a next-generation factor VIIa (FVIIa) molecule.